Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 98


Targeting of Rac GTPases blocks the spread of intact human breast cancer.

Katz E, Sims AH, Sproul D, Caldwell H, Dixon MJ, Meehan RR, Harrison DJ.

Oncotarget. 2012 Jun;3(6):608-19.


Inhibition of the Rho GTPase, Rac1, decreases estrogen receptor levels and is a novel therapeutic strategy in breast cancer.

Rosenblatt AE, Garcia MI, Lyons L, Xie Y, Maiorino C, Désiré L, Slingerland J, Burnstein KL.

Endocr Relat Cancer. 2011 Feb 23;18(2):207-19. doi: 10.1677/ERC-10-0049. Print 2011 Apr.


Specificity and mechanism of action of EHT 1864, a novel small molecule inhibitor of Rac family small GTPases.

Shutes A, Onesto C, Picard V, Leblond B, Schweighoffer F, Der CJ.

J Biol Chem. 2007 Dec 7;282(49):35666-78. Epub 2007 Oct 11.


Characterization of EHT 1864, a novel small molecule inhibitor of Rac family small GTPases.

Onesto C, Shutes A, Picard V, Schweighoffer F, Der CJ.

Methods Enzymol. 2008;439:111-29. doi: 10.1016/S0076-6879(07)00409-0.


Rac1 and Rac3 isoform activation is involved in the invasive and metastatic phenotype of human breast cancer cells.

Baugher PJ, Krishnamoorthy L, Price JE, Dharmawardhane SF.

Breast Cancer Res. 2005;7(6):R965-74. Epub 2005 Sep 30.


STAT3 activation in HER2-overexpressing breast cancer promotes epithelial-mesenchymal transition and cancer stem cell traits.

Chung SS, Giehl N, Wu Y, Vadgama JV.

Int J Oncol. 2014 Feb;44(2):403-11. doi: 10.3892/ijo.2013.2195. Epub 2013 Nov 29.


Honokiol inhibits epithelial-mesenchymal transition in breast cancer cells by targeting signal transducer and activator of transcription 3/Zeb1/E-cadherin axis.

Avtanski DB, Nagalingam A, Bonner MY, Arbiser JL, Saxena NK, Sharma D.

Mol Oncol. 2014 May;8(3):565-80. doi: 10.1016/j.molonc.2014.01.004. Epub 2014 Jan 15.


Characterization of EHop-016, novel small molecule inhibitor of Rac GTPase.

Montalvo-Ortiz BL, Castillo-Pichardo L, Hernández E, Humphries-Bickley T, De la Mota-Peynado A, Cubano LA, Vlaar CP, Dharmawardhane S.

J Biol Chem. 2012 Apr 13;287(16):13228-38. doi: 10.1074/jbc.M111.334524. Epub 2012 Mar 1.


C-X-C motif chemokine 12/C-X-C chemokine receptor type 7 signaling regulates breast cancer growth and metastasis by modulating the tumor microenvironment.

Wani N, Nasser MW, Ahirwar DK, Zhao H, Miao Z, Shilo K, Ganju RK.

Breast Cancer Res. 2014 May 29;16(3):R54. doi: 10.1186/bcr3665.


Rac1 contributes to trastuzumab resistance of breast cancer cells: Rac1 as a potential therapeutic target for the treatment of trastuzumab-resistant breast cancer.

Dokmanovic M, Hirsch DS, Shen Y, Wu WJ.

Mol Cancer Ther. 2009 Jun;8(6):1557-69. doi: 10.1158/1535-7163.MCT-09-0140. Epub 2009 Jun 9.


Breast cancer-specific mutations in CK1epsilon inhibit Wnt/beta-catenin and activate the Wnt/Rac1/JNK and NFAT pathways to decrease cell adhesion and promote cell migration.

Foldynová-Trantírková S, Sekyrová P, Tmejová K, Brumovská E, Bernatík O, Blankenfeldt W, Krejcí P, Kozubík A, Dolezal T, Trantírek L, Bryja V.

Breast Cancer Res. 2010;12(3):R30. doi: 10.1186/bcr2581. Epub 2010 May 27.


Anticancer activity of litchi fruit pericarp extract against human breast cancer in vitro and in vivo.

Wang X, Yuan S, Wang J, Lin P, Liu G, Lu Y, Zhang J, Wang W, Wei Y.

Toxicol Appl Pharmacol. 2006 Sep 1;215(2):168-78. Epub 2006 Mar 23.


Activated Rac1 requires gp130 for Stat3 activation, cell proliferation and migration.

Arulanandam R, Geletu M, Feracci H, Raptis L.

Exp Cell Res. 2010 Mar 10;316(5):875-86. doi: 10.1016/j.yexcr.2009.10.017. Epub 2009 Oct 21.


Preclinical development of novel Rac1-GEF signaling inhibitors using a rational design approach in highly aggressive breast cancer cell lines.

Cardama GA, Comin MJ, Hornos L, Gonzalez N, Defelipe L, Turjanski AG, Alonso DF, Gomez DE, Menna PL.

Anticancer Agents Med Chem. 2014;14(6):840-51.


Loss of interferon regulatory factor 5 (IRF5) expression in human ductal carcinoma correlates with disease stage and contributes to metastasis.

Bi X, Hameed M, Mirani N, Pimenta EM, Anari J, Barnes BJ.

Breast Cancer Res. 2011;13(6):R111. doi: 10.1186/bcr3053. Epub 2011 Nov 4.


Alantolactone selectively suppresses STAT3 activation and exhibits potent anticancer activity in MDA-MB-231 cells.

Chun J, Li RJ, Cheng MS, Kim YS.

Cancer Lett. 2015 Feb 1;357(1):393-403. doi: 10.1016/j.canlet.2014.11.049. Epub 2014 Nov 27.


Inhibition of prostate smooth muscle contraction and prostate stromal cell growth by the inhibitors of Rac, NSC23766 and EHT1864.

Wang Y, Kunit T, Ciotkowska A, Rutz B, Schreiber A, Strittmatter F, Waidelich R, Liu C, Stief CG, Gratzke C, Hennenberg M.

Br J Pharmacol. 2015 Jun;172(11):2905-17. doi: 10.1111/bph.13099. Epub 2015 May 5.


A Rac-Pak signaling pathway is essential for ErbB2-mediated transformation of human breast epithelial cancer cells.

Arias-Romero LE, Villamar-Cruz O, Pacheco A, Kosoff R, Huang M, Muthuswamy SK, Chernoff J.

Oncogene. 2010 Oct 28;29(43):5839-49. doi: 10.1038/onc.2010.318. Epub 2010 Aug 16.


Functional analysis of Zyxin in cell migration and invasive potential of oral squamous cell carcinoma cells.

Yamamura M, Noguchi K, Nakano Y, Segawa E, Zushi Y, Takaoka K, Kishimoto H, Hashimoto-Tamaoki T, Urade M.

Int J Oncol. 2013 Mar;42(3):873-80. doi: 10.3892/ijo.2013.1761. Epub 2013 Jan 4.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk